Taysha Gene Therapies Income After Taxes 2020-2024 | TSHA
Taysha Gene Therapies income after taxes from 2020 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Taysha Gene Therapies Annual Income After Taxes
(Millions of US $) |
| 2023 |
$-112 |
| 2022 |
$-166 |
| 2021 |
$-175 |
| 2020 |
$-60 |
| 2019 |
$ |
Taysha Gene Therapies Quarterly Income After Taxes
(Millions of US $) |
| 2024-06-30 |
$-21 |
| 2024-03-31 |
$-24 |
| 2023-12-31 |
$48 |
| 2023-09-30 |
$-117 |
| 2023-06-30 |
$-25 |
| 2023-03-31 |
$-18 |
| 2022-12-31 |
$-55 |
| 2022-09-30 |
$-27 |
| 2022-06-30 |
$-34 |
| 2022-03-31 |
$-50 |
| 2021-12-31 |
$-50 |
| 2021-09-30 |
$-51 |
| 2021-06-30 |
$-41 |
| 2021-03-31 |
$-32 |
| 2020-12-31 |
$-18 |
| 2020-09-30 |
$-15 |
| 2020-06-30 |
$-21 |
| 2020-03-31 |
$-5 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.449B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
